• English
  • Français
  • Español
  • Facebook
  • RSS
  • Twitter

Therapeutics Initiative

Independent Healthcare Evidence

  • TI
  • About Us
    • Oversight Committee
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
    • Questions & Answers
  • Therapeutics Letter
  • Our Evidence Reviews
  • Portrait
  • Continuing Education
  • Contact Us
  • Subscribe
Home > Education > [Mar 17] Therapeutics Initiative Best Evidence Webinar: Withdrawal of antihypertensive drugs in older people

[Mar 17] Therapeutics Initiative Best Evidence Webinar: Withdrawal of antihypertensive drugs in older people

February 8, 2021 Education, Podcasts & Videos 3 Comments

Share

TI Best Evidence Webinar


TITLE: Withdrawal of antihypertensive drugs in older people

PRESENTER: Dr. Emily Reeve is a pharmacist and Senior Research Fellow in the Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical and Health Sciences, at the University of South Australia. Dr Reeve is currently supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Grant. Her research focuses on optimising medication use through deprescribing in older adults and people living with dementia. She has a particular interest in consumer attitudes towards deprescribing and the development of deprescribing guidelines.


This webinar has already taken place. Scroll down to view a video recording of the event.


DATE: Wednesday, March 17th, 2021

TIME: 19:00 – 20:00 Pacific Standard Time PST [UTC -7 convert to your local time]

CME CREDITS: MainPro+/MOC Section 1 credits: 1.0. You must register, attend the webinar and complete the evaluation in order to receive your certificate.

Learning Objectives

  • An understanding of the process of conducting a Cochrane systematic review
  • Knowledge of the potential benefits and harms of withdrawal of antihypertensives used for hypertension or primary prevention of cardiovascular disease in older adults
  • An appreciation of the limitations of evidence as well as considerations for future research in this field
  • Knowledge of factors to consider when determining whether deprescribing of antihypertensives is appropriate in older adults
https://www.ti.ubc.ca/wordpress/wp-content/uploads/2021/03/Withdrawal_Antihypertensives_Older_People.m4v

Comments

  1. Melanie says

    March 22, 2021 at 12:12 pm

    Excellent presentation that underscores the issues facing clinicians: BP targets, preventative medications (e/g statins, ASA),

    This presentation kind of underscored the difficulty in deciding what targets are acceptable for the elderly as there are just so many targets (CKD, CM, HTN) and no real guidance in the case of the elderly, so we tend to treat to “tight targets” which may not be appropriate. Would be great to have some “standard” guidelines for the elderly.
    How often to monitor BP and with what goal?

    Reply
    • Alan Cassels @ TI says

      March 23, 2021 at 12:41 pm

      Hi Melanie.
      Just responding to your note to the Therapeutics Initiative. We addressed the issue of hypertension treatment of the elderly in a newsletter which you can find here:
      https://www.ti.ubc.ca/2008/10/31/treatment-of-elevated-blood-pressure-in-the-very-elderly-less-is-better/
      Thank you for your comments.
      Cheers, Alan Cassels

      Reply
  2. Leon Petruniak says

    March 29, 2021 at 12:00 pm

    a few thoughts (bedside to bench/or endpoint collector… (1) geriatrics by necessity is a heterogeneous group, and balancing polymorb + polypharm is often a tightrope, sometimes with dental floss. BP targets, 1,2.3’ary management, and most endpoints aside most in this cohort are overtreated with antiBP agents. (2) frailty must be captured using objective measures, but also there must be a clinical gestalt to inform treatment/management. (3) NNT major CV event vs NNH major traumatic event from OH (head bleed, hip # – this group also dies), much like basic EBM — it all depends. Thanks for archiving this great lecture, originally registered but ended up on call.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

 

  • About Us
    • Oversight Committee
    • Questions & Answers
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
  • Portrait
    • Frequently Asked Questions
    • Portrait Contact
  • Therapeutics Letter
  • Our Evidence Reviews
  • Get Involved
  • Continuing Education
    • Best Evidence
  • Contact Us
  • Terms & Policies
    • Legal Information & Terms of Use
    • Privacy Policy
    • Acceptable Use Policy

Categories

  • News (123)
  • Therapeutics Letter (133)
  • Portrait (1)
  • Drug Assessments (39)
  • PharmacoEpidemiology (75)
  • Podcasts & Videos (56)

Recent Seminars

[Apr 14] Therapeutics Initiative Best Evidence Webinar: Optimising Outcomes in Persons with Carotid Stenosis: Where are we up to in April 2021?

Register
Share

[Apr 28] TI Methods Speaker Series: The PRISMA 2020 Statement

Register
Share

Methods Speaker Series 2021

Share

Therapeutics Initiative

Our mission is to provide physicians, nurse practitioners, pharmacists, allied health professionals, and the public with up-to-date, independent, evidence-based, practical information on healthcare interventions. Read more Donate

Contact

2176 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3
Contact us
Office: +1 604-822-0700
Fax: +1 604-822-0701

UBC logoISDB logo

Subscribe

Subscribe to receive email notifications from the TI about the Therapeutics Letter, upcoming educational events, personal prescribing portraits and other news and recent publications. SUBSCRIBE

© 1994 - 2021 Therapeutics Initiative · Terms & Policies · TM